Antibiotics

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.

This study was one of the largest to address the use of IV ceftriaxone in the context of MSSA bacteremia compared with cefazolin.

Telemedicine use is likely to continue expanding even as the COVID-19 pandemic slowly resolves.

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.

It was a week marked by significant FDA decisions and COVID-19 treatment updates.

Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment option, it’s a promise of safety and standardization.

A clinician offers insight into what he sees in terms of these therapies and the need to get more information to those providers in the field as well as access to them.

COVID-19 hospital patients were prescribed 21.81% more antibiotics than patients without COVID-19. How did this affect their risk of coinfection?

With the proliferation of therapies for skin and soft tissue infections (SSTIs), a clinician discusses how providers can appropriately find the balance between these novel therapies, the existing treatment guidelines, and stewardship.

A clinician has a novel approach to patient conversations around this topic to determine if they want to assess if their penicillin allergies truly present a problem for treatment.

In episode 1 of this short video series, a clinician discusses what types of patients are best suited for inpatient or outpatient care for these infections.

Tonight, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product, intended to prevent recurrent C difficile infection in adults.

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

The company says it plans to begin talking with regulators next year after seeing positive efficacy data in the trials.

One clinician discusses strategies in how his institution minimizes the wide spectrum approach to antibiotics as well as tries to prevent potential complications.

In episode 1 of this short video series, a clinician discusses his experience in what his institution is seeing as well as how they handle their treatment protocol and stewardship where possible.

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.

Lodise breaks down significant findings from his 8 IDWeek 2022 posters.

Demystifying clinical data for treating invasive AmpC-harboring Enterobacterales.

Entasis presented follow-up data for its therapy, sulbactam-durlobactam (SUL-DUR), and its phase 3 ATTACK trial. The company is looking at a potential mid-2023 regulatory approval.

Encouraging ICU physicians to utilize rapid diagnostics, like the FilmArray Pneumonia Panel, may improve patient outcomes.

The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing held a virtual winter meeting and a hybrid summer meeting in 2022. Ad hoc working groups have several breakpoint revisions underway for multiple organism-drug combinations.

Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.

Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.

The phase 3 study met its primary and secondary end points of all-cause mortality, microbiological eradication rates, and new Staphylococcus aureus bacteremia complications.

At IDWeek 2022, Erica Stohs, MD, MPH, presented surprising findings about unnecessary antibiotics in a cohort coinfected with COVID-19 and pneumonia.

There is a significant need for C difficile treatments that don’t destroy the microbiome.

At IDWeek 2022, antimicrobial stewardship was front and center. However, not all tests are created equal.

Antimicrobial stewardship works, one IDWeek 2022 study found.

A 2-hour intermittent infusion of ceftazidime-avibactam with aztreonam (ATM) is safe, but clinicians should exercise caution when prescribing continuous infusion ATM.